Isatuximab
Based on 1 publication(s) in Google Scholar
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38, a protein highly expressed on hematological malignant cells, including those in multiple myeloma (MM). Isatuximab has antitumor activity via multiple biological mechanisms, including antibody-dependent cellular-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 ectoenzyme activity, which is implicated in many cellular functions.
For research use only. We do not sell to patients.
- Purity: 98.5%
- CAS No.: 1461640-62-9
- Molecular Weight:145.2 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Isatuximab
More
Biological Activity
Human IgG1 kappa
Human
CD38
An in-vitro study shows that the combination of Isatuximab with Pomalidomide results in greater direct toxicity and lysis of CD38 multiple myeloma cells by effector cells compared with Isatuximab alone[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized CD38 Protein, Human can bind Isatuximab. The EC50 for this effect is 6.163 ng/mL. -
Flow Cytometry analysis of Raji cells labelling CD38 (red) with Isatuximab (anti-CD38) (HY-P9976). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 1461640-62-9
-
Appearance Liquid
-
Molecular Weight 145.2 kDa
-
Color Colorless to light yellow
-
SMILES
[Isatuximab]
-
Synonyms
ch38SB19; hu38SB19; SAR-650984
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
NAD+ exhaustion by CD38 upregulation contributes to blood pressure elevation and vascular damage in hypertension. [Abstract]2023 Sep 18;8(1):353. PMID: 37718359
Purity & Documentation
-
Data Sheet (259 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Dhillon S. Isatuximab: First Approval [published correction appears in Drugs. 2020 May 23;:]. Drugs. 2020;80(9):905-912. [Content Brief]
[2]. Attal M, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study [published correction appears in Lancet. 2019 Dec 7;394(10214):2072]. Lancet. 2019;394(10214):2096-2107. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)